je.st
news
The $10 Billion Reason That This Tiny Biotech Stock Could Soar
2015-02-22 17:00:08| Biotech - Topix.net
If Portola can demonstrate that betrixaban can control bleeding in hospital and post-discharge patients, it could become a big player in the $10 billion market for anticoagulants. Displacing a long-standing leader Warfarin has been used for decades by doctors to help keep blood flowing freely in heart disease and post-operative patients.
Tags: stock
reason
billion
tiny
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||